Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received ¹⁷⁷Lu-PSMA-617: Importance of ¹⁸F-FDG-Avid Discordant Findings.","authors":"Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S Nelson, Heather H Cheng, Todd A Yezefski, Michael C Haffner, Jessica E Hawley, Robert B Montgomery, Evan Y Yu, Michael T Schweizer, Delphine L Chen, Amir Iravani","doi":"10.2967/jnumed.124.268167","DOIUrl":"10.2967/jnumed.124.268167","url":null,"abstract":"<p><p>The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with ¹⁷⁷Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION and required ¹⁸F-FDG PET to exclude patients with discordant findings. Although the screen-failed patients had shorter overall survival (OS) than those treated with LuPSMA, it remains unclear whether their outcomes might have been modified if they had been exposed to LuPSMA. In this study, we evaluated associations between the TheraP eligibility criteria and subgroups and the treatment outcomes of patients who were deemed suitable and treated on the basis of VISION criteria. <b>Methods:</b> Consecutive patients who were treated with LuPSMA and who underwent pretreatment PSMA and ¹⁸F-FDG PET were classified as TheraP-eligible (TheraP-E) and TheraP-ineligible (TheraP-I), the latter of which were subclassified as low PSMA or discordant. Odds ratios for an at least 50% decline in prostate-specific antigen (PSA50) were computed using logistic regression, and hazard ratios (HRs) for PSA progression-free survival (PSA-PFS) and OS were computed using Cox regressions. Multivariable analyses were adjusted for baseline imaging and clinical parameters. <b>Results:</b> Of 75 patients, 31 (41%) were deemed TheraP-I; of those, 24 were subclassified as having discordant disease. TheraP-I patients had a lower PSA50 rate than that of TheraP-E patients (28% vs. 67%; odds ratio, 0.19; 95% CI, 0.06-0.52; <i>P</i> = 0.002) and a higher risk of PSA progression (HR, 2.0; 95% CI, 1.2-3.3; <i>P</i> = 0.007). OS in the TheraP-I group was numerically shorter than in the TheraP-E group, but the comparison was only marginally significant (10.4 mo vs. not reached; HR, 1.9; 95% CI, 1.0-3.7; <i>P</i> = 0.054). TheraP-I patients with low PSMA had no significantly different risk of death (<i>P</i> = 0.9) from that of TheraP-E patients, but those with discordant findings had higher risk of death (HR, 2.3; 95% CI, 1.1-4.6; <i>P</i> = 0.02). Discordant disease remained prognostic for OS after adjusting for baseline imaging and clinical parameters (HR, 3.0; 95% CI, 1.3-6.8; <i>P</i> = 0.01). <b>Conclusion:</b> In VISION-eligible patients who were treated with LuPSMA, TheraP-I patients with discordant findings had lower PSA50, PSA-PFS, and OS. Our study suggests that the shorter OS of TheraP-I patients is mainly driven by the presence of discordant disease.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"47-53"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹¹C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to Cyclooxygenase-1 in the Human Brain.","authors":"Nafiseh Ghazanfari, Jeih-San Liow, Min-Jeong Kim, Raven Cureton, Adrian Lee, Carson Knoer, Madeline Jenkins, Jinsoo Hong, Jose A Montero Santamaria, H Umesha Shetty, Anthony Galassi, Paul Wighton, Martin Nørgaard, Douglas N Greve, Sami S Zoghbi, Victor W Pike, Robert B Innis, Paolo Zanotti-Fregonara","doi":"10.2967/jnumed.124.267928","DOIUrl":"10.2967/jnumed.124.267928","url":null,"abstract":"<p><p>Our laboratory recently developed [¹¹C]PS13 as a PET radioligand to selectively measure cyclooxygenase-1 (COX-1). The cyclooxygenase enzyme family converts arachidonic acid into prostaglandins and thromboxanes, which mediate inflammation. The total brain uptake of [¹¹C]PS13, which is composed of both specific binding and background uptake, can be accurately quantified with gold standard methods of compartmental modeling. This study sought to quantify the specific binding of [¹¹C]PS13 to COX-1 in healthy human brain using scans performed with arterial input function at baseline and after blockade by the COX-1-selective inhibitor ketoprofen. <b>Methods:</b> Eight healthy volunteers underwent two 90-min [¹¹C]PS13 PET scans with radiometabolite-corrected arterial input function, at baseline and about 2 h after oral administration of ketoprofen (75 mg). <b>Results:</b> Two-tissue compartment modeling effectively identified the total uptake of radioactivity in the brain (as distribution volume), showing the highest densities in the hippocampus, the occipital cortex, and the banks of the central sulcus. All brain regions exhibited displaceable and specific binding, and thus none could be used as a reference region. Ketoprofen blocked approximately 84% of the binding sites on COX-1 in the whole brain. After full occupancy was extrapolated, the average whole-brain values of [¹¹C]PS13 were 1.6 ± 0.8 mL·cm^-3 for specific uptake, 1.7 ± 0.6 mL·cm^-3 for background uptake, and 1.1 ± 0.5 for the specific-to-background ratio. The hippocampus had the highest specific-to-background ratio value of 2.7 ± 0.9. <b>Conclusion:</b> [¹¹C]PS13 exhibited high specific binding to COX-1 in the human brain, but its quantification requires arterial blood sampling.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"117-122"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":"66 1","pages":"149"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Comparison of Cabazitaxel Versus ¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.","authors":"Mike Wenzel, Florestan Koll, Benedikt Hoeh, Clara Humke, Carolin Siech, Nicolai Mader, Amir Sabet, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Christian Brandts, Severine Banek, Felix K H Chun, Philipp Mandel","doi":"10.2967/jnumed.124.268807","DOIUrl":"10.2967/jnumed.124.268807","url":null,"abstract":"<p><p>¹⁷⁷Lu-vipivotide tetraxetan prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) therapy is under current scientific investigation and aims to become established in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, real-world evidence in treatment comparison is scant. <b>Methods:</b> We relied on the FRAMCAP database and compared cabazitaxel versus ¹⁷⁷Lu-PSMA therapy in mCRPC patients regarding progression-free survival (PFS) and overall survival (OS). Sensitivity analyses addressed second- to fourth-line mCRPC treatment to approximate current phase III patient selection criteria. <b>Results:</b> Of 373 patients, 14% received cabazitaxel, 65% received ¹⁷⁷Lu-PSMA, and 21% received both. Patients undergoing ¹⁷⁷Lu-PSMA therapy were significantly older than cabazitaxel patients (median, 72 y vs. 66 y; <i>P</i> < 0.01), and a higher proportion had an Eastern Cooperative Oncology Group score of 2 or more (12% vs. 5.0%, <i>P</i> = 0.1). Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for ¹⁷⁷Lu-PSMA versus cabazitaxel. In outcome analyses, significant superior median PFS was observed for ¹⁷⁷Lu-PSMA versus cabazitaxel (13.4 mo vs. 7.1 mo, <i>P</i> < 0.001), even after multivariable adjustment (hazard ratio, 0.38; <i>P</i> < 0.001). Regarding OS, rates also significantly differed, with median OS of 14.7 mo versus 16.5 mo versus 29.6 mo for cabazitaxel versus ¹⁷⁷Lu-PSMA versus both treatments (<i>P</i> < 0.01). In sensitivity analyses of second- to fourth-line mCRPC treatment, PFS rates and median OS rates for cabazitaxel versus ¹⁷⁷Lu-PSMA versus both therapies qualitatively remained the same as for the entire cohort. <b>Conclusion:</b> In a real-world setting, ¹⁷⁷Lu-PSMA provides significantly better PFS and qualitatively better OS rates than does cabazitaxel chemotherapy and should therefore be considered a valuable treatment option for advanced mCRPC patients according to the European Medicines Agency approval.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"61-66"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meningioma Revisited: Should Whole-Body Staging with [⁶⁸Ga]Ga-DOTATOC PET/CT of High-Grade Meningiomas Become Standard Practice?","authors":"Ekin Ermiş, Nicolas Bachmann, Katharina Lutz, Thomas Pyka","doi":"10.2967/jnumed.124.267934","DOIUrl":"10.2967/jnumed.124.267934","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"162"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Routine Dosimetry Really Happening?","authors":"John J Sunderland","doi":"10.2967/jnumed.124.267830","DOIUrl":"https://doi.org/10.2967/jnumed.124.267830","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":"66 1","pages":"20-23"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.","authors":"Thomas A Hope, Jeremie Calais, Ajit H Goenka, Uwe Haberkorn, Mark Konijnenberg, Jonathan McConathy, Daniela E Oprea-Lager, Laura Trimnal, Elcin Zan, Ken Herrmann, Christophe M Deroose","doi":"10.2967/jnumed.124.269002","DOIUrl":"10.2967/jnumed.124.269002","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"26-33"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPECT Deserves RESPECT: The Potential of SPECT/CT to Optimize Patient Outcomes with Theranostics Therapy.","authors":"Louise Emmett","doi":"10.2967/jnumed.124.268325","DOIUrl":"https://doi.org/10.2967/jnumed.124.268325","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Banner Year for Nuclear Medicine, Molecular Imaging, and Theranostics.","authors":"Cathy Sue Cutler","doi":"10.2967/jnumed.6512PresMessage","DOIUrl":"https://doi.org/10.2967/jnumed.6512PresMessage","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":"65 12","pages":"7A-8A"},"PeriodicalIF":0.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changed Regulation Enables Pragmatic Solution for Cancer Patients.","authors":"Uwe Holzwarth","doi":"10.2967/jnumed.124.268945","DOIUrl":"10.2967/jnumed.124.268945","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1850"},"PeriodicalIF":0.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}